At this year’s virtual meeting, registered participants were able to watch live and pre-recorded sessions, including presentations and discussions.
Patients attending clinics at the Danish Headache Center, Copenhagen, will be invited to undergo CGRP provocation testing to try and identify those most likely to respond to anti-CGRP therapies. Describing plans to investigate the potential of CGRP provocation testing as a predictive biomarker, Professor Messoud Ashina explained that previous research has shown that about 66% …
Read more »Treating migraine attacks with ubrogepant when headaches are mild rather than moderate/severe doubles the likelihood of pain freedom at 2 hours, according to data from a Phase 3, open label, 52-week extension trial of patients who had completed the ACHIEVE I or II trials. Other symptoms – phonophobia, photophobia and nausea – were also more …
Read more »Clinicians need to be aware of the potential consequences of COVID-19 infection in patients with migraine, particularly in relation to their increased risk of cardiovascular disease (CVD). In her review of migraine issues during the COVID-19 pandemic, Dr Antoinette Maassen van den Brink, from Erasmus MC, Rotterdam, The Netherlands, highlighted two newly published studies that …
Read more »Hypersensitivity to CGRP infusion has been demonstrated in patients with post-traumatic headache (PTH) and suggests a role for anti-CGRP therapies in this population. Dr Håkan Ashina from the Danish Headache Center, Copenhagen, reported results of a randomised, double-blind, placebo-controlled, 2-way crossover study of 34 patients with persistent PTH. Following intravenous infusion of 1.5 µg/min of …
Read more »Women with both migraine and endometriosis show menstrual cycle-dependent changes in CGRP plasma levels, with higher concentrations during menstruation. Dr Bianca Raffaelli from Charité Universitätsmedizin Berlin, Germany, explained that these findings suggest a common epidemiological background for both diseases with a prominent role for CGRP in comorbid patients. As CGRP plays a role in the …
Read more »Erenumab may significantly reduce monthly migraine days (MMDs) and monthly headache days (MHDs) in patients with idiopathic intracranial hypertension (IIH) in ocular remission, with chronic migraine-like headaches, according to results of a prospective, open label study. In the real world study of 55 patients, erenumab 70 mg reduced MMDs at six months by 10.3±4.8 (P<0.001) …
Read more »A 120 mg sc monthly dose of fremanezumab for paediatric patients <45 kg in weight has been selected for Phase 3 trials based on the results of a pharmacokinetic model and simulation approach. A virtual population of 2400 paediatric patients aged 6-17 was generated and used together with a refinement of the adult fremanezumab population …
Read more »
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
